Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

Trial Profile

AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Adverse reactions; Registrational
  • Acronyms IMPALA-EX; IMPALA-X
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2019 According to a Savara Pharmaceuticals media release, enrollment in this study continues to be active.
    • 25 Jul 2018 According to a Savara Pharmaceuticals media release, ten subjects have enrolled to date in this trial. Submission of the Molgradex Biologic License Application is expected in the first half of 2020.
    • 09 May 2018 According to the Savara Pharmaceuticals media release, first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top